Bank of America allocates over $250 million annually for GLP-1 weight loss drugs, CEO Brian Moynihan revealed, emphasizing the health benefits and long-term value for employees.
BofA spends over $2 billion a year on healthcare for its roughly 211,000 employees
Aug 06, 2026
01:07 pm
What's the storyBank of America (BoA) is spending over $250 million annually to provide GLP-1 weight loss drugs to its employees.
The company's CEO Brian Moynihan revealed the information in an interview with CNBC.
Bank of America spending $250M a year on GLP-1 weight loss drugs
Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says | Fortune
Bank of America spends more than $250 million on GLP-1s
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investm
Major bank spends $250 million a year on GLP-1 drugs for its employees, CEO says
Bank of America defiende gastar 250 millones al año en fármacos contra la obesidad para sus trabajadores (y no es el único)
Får Ozempic på jobbet – kostar miljarder
As companies in America face rising health costs, Starbucks ends employee benefits' coverage for these medicines
Starbucks is cutting GLP-1 coverage for weight loss as employer costs climb
